KGK, CAHS enter letter of intent

KGK, CAHS enter letter of intent

Pending due diligence, KGK Synergize will enter into a definitive partnership agreement with the Center for Applied Health Sciences.

KGK Synergize Inc., a contract research organization (CRO) offering human clinical trials to the health nutrition industry, has entered into a non-binding letter of intent with the Center for Applied Health Sciences (CAHS). CAHS is a U.S.-based CRO catering to the natural health products/dietary supplement industry with a special focus on human performance and sports nutrition. Pending satisfactory completion of due diligence, KGK Synergize will enter into a definitive partnership agreement with CAHS. The final announcement outlining the structure of KGK's acquisition and details of the agreement are expected to be finalized prior to the end of the current calendar year.

“This partnership is very exciting for KGK as it allows us instant access into the U.S. Market,” stated Najla Guthrie, president and CEO of KGK Synergize Inc. “The partnership will also open up the door for us to have strong presence in the sports nutrition industry. We are looking forward to the senior management team and executives at CAHS playing a key role in the growth and success of KGK Synergize U.S. Inc.”

“With our recent expansion into the pharmaceutical, nutraceutical and medical food industries, this potential strategic partnership with KGK is timely as we look to accelerate the growth of CAHS,” commented Hector Lopez, MD, CSCS, FAAPMR, Principal and CMO of CAHS. “KGK shares in many of the core values and vision of CAHS. That shared vision is to galvanize and push the forefront of the industry as a center of excellence by providing unique solutions in the dietary supplement and natural health products industry via not only cutting-edge R&D, but also by assisting forward-thinking client companies with critical elements of their branding, marketing and risk management platforms.”

“KGK has established themselves as a leading CRO and our team is excited about the possibility to help grow both the KGK and CAHS brands,” said Tim Ziegenfuss, PhD, CSCS, FISSN, Founder and CEO of CAHS. “Their expertise in clinical trial design, project management, and rapid publication of data will help us streamline our services for current and future CAHS clients. Ultimately, this partnership will help establish KGK and CAHS as worldwide leaders in human clinical trial research.”



Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.